Amira Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Panmira Pharmaceuticals, LLC

Other

Brickell Biotech, Inc.

Bowei Wang

Jeannie M Arruda

Thomas Jon Seiders

John Howard Hutchinson

Brian Andrew Stearns

Jeffrey Roger Roppe

Nicholas D Smith

Jean-Michel Andre Vernier

Dehua Huang

Nicholas Simon Stock

Nicholas David Cosford

Benito Munoz

Yen Truong

Joseph E Payne

Brian Walter Eastman

Lida R Tehrani

Scott D Edmondson

Ping Liu

Heather Renee Coate

Harold B Wood

Gregori J Morriello

Cheng Zhu

Lucy Xiumin Zhao

Ryan Christopher Clark

Brian T Campbell

Andrew William Stamford

William K Hagmann

Ravi P Nargund

Hubert B Josien

Qun Dang

Bin Hu

Barbara A Pio

Michael W Miller

Shankar Venkatraman

Duane E DeMong

Purakkattle J Biju

Alec D Lebsack

Milana M Maletic

Linus S Lin

Bing Li

Harry R Chobanian

Rajan Anand

Wanying Sun

Timothy A Blizzard

Deborah Volkots

Jill Melissa Scott

Timothy Andrew Parr

Xiumin Zhao

Jason W Szewczyk

Steve Fong Poon

Thomas Jonathan Seiders

Chris King

Liping Wang

Yuping Zhu

Zhiqiang Guo

Zhiyong Hu

Zhengxia Chen

Nicholas D P Cosford

William Bert Geiss

Weichao George Chen

Lehua Chang

Joel M Harris

Vincent Colandrea

Celine Bonnefous

Timothy Allen Blizzard

Meibi Dai

Nam Fung Kar

Kake Zhao

Dann Parker

Candido Gude

Mingxiang Cui

Yong Huang

Rowena Villanueva Cube

Janet Lorraine Gunzer

Kuman Srinivasan

Zaihong Zhang

Ying Lv

Lili Tian

Yem Pham Truong

Megan Macala

Yen Pham Truong

Nicholas D Cosford

Vincent J Colandrea

Duane E Demong

William B Geiss

Timothy Parr

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Compounds as lysophosphatidic acid receptor antagonists

Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis

Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. 

Substituted cyclopropyl compounds useful as GPR119 agonists

Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. 

Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment

The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.

Thiazolyl mGluR5 antagonists and methods for their use

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGDreceptors described herein, as well as methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

[object Object]

Antagonists of lysophosphatidic acid receptors

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGDreceptors. Also described herein are methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors

Polycyclic antagonists of lysophosphatidic acid receptors

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGDreceptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

Antagonists of prostaglandin D2 receptors

Growing community of inventors

Westfield, NJ, United States of America

Bowei Wang